Iodomarin 200, tablets 0.2 mg 100 pcs

Pharmacotherapeutic group: Thyroxine synthesis regulator – iodine drug

ATC code: H03CA

Pharmacological properties

Pharmacodynamics

Iodine is a vital trace element that is an integral part of the thyroid hormones thyroxine and triiodothyronine. Thyroid hormones are involved in the development of all organs and systems, in the regulation of metabolic processes in the body: they are responsible for the exchange of protein, fat, carbohydrates and energy in the body, regulate the activity of the brain, nervous and cardiovascular system, mammary glands, as well as the growth and development of children.

Iodine deficiency is especially dangerous for children, teenagers, pregnant and lactating women.

Pharmacokinetics

absorption.

Potassium iodide is almost completely absorbed in the small intestine when ingested.

Distribution

The average distribution for healthy individuals is approximately 23 liters (38% body weight). Plasma concentration of iodine is normal at 0.1 to 0.5 µg/dL. It accumulates in the thyroid gland, salivary glands, mammary glands, and gastric tissues. Concentrations in saliva, gastric juice and breast milk are about 30 times higher than in blood plasma.

Elimination

Extracted by the kidneys, the concentration of iodine in the urine relative to creatinine (µg/g) is an indicator of its intake.

Indications

• prevention of iodine deficiency diseases, including. endemic goiter (especially in pregnant and nursing women);
• prevention of goiter recurrence after goiter surgical removal or after goiter treatment with thyroid hormones;
• treatment of diffuse euthyroid goiter in newborns, children, teenagers, and young adult patients.

.

Active ingredient

Potassium iodide

Composition

Composition per tablet:

Active substance:potassium iodide – 0.262 mg (corresponding to 0.2 mg of iodine). Excipients:lactose monohydrate, magnesium hydroxycarbonate, gelatin, sodium carboxymethyl starch, colloidal silicon dioxide, magnesium stearate.

How to take, the dosage

In determining the required dose of the drug Iodomarin ^® 200 it is necessary to take into account regional and individual characteristics of iodine intake with food. This is especially important when prescribing the drug to newborns and children under 4 years of age. Prevention of iodine deficiency diseases:

Infants and children: 100 mcg of iodine per day ( 1/ 2 tablets of Iodomarin ^® 200); Adolescents and adults: 100-200 mcg of iodine per day ( 1/ 2 to 1 tablet of Iodomarin ^® 200);

Pregnancy and during breastfeeding: 100-200 mcg of iodine per day ( 1/ 2 to 1 tablet of Iodomarin ^® 200).

Prevention of goiter recurrence after goiter surgical removal or after completion of goiter treatment with thyroid hormone drugs:

100-200 mcg of iodine per day ( 1/ 2 to 1 tablet of Iodomarin ^® 200).

Treatment of euthyroid goiter:

Infants and children: 100-200 mcg of iodine per day ( 1/ 2 to 1 tablet of Iodomarin ^® 200);

Adolescent and adult patients of young age:

200 mcg of iodine per day (1 tablet of Iodomarin ^® 200).

The daily dose of the drug should be taken in a single dose, after a meal, with plenty of fluids. When prescribing the drug in infants and children under 3 years of age it is recommended to dissolve the tablet in a small amount (1 tablespoon) of boiled water at room temperature.

The use of the drug for prophylactic purposes is usually for several months or years, and often for life.

To treat goiter in newborns, 2-4 weeks is sufficient in most cases; in children, adolescents, and adults, 6-12 months or more is usually required. The length of treatment is determined by the doctor.

Interaction

Iodine deficiency increases and excess iodine decreases the effectiveness of antithyroid therapy. Therefore, before or during treatment of hyperthyroidism, it is recommended to avoid all iodine intake if possible. On the other hand, antithyroid drugs inhibit the conversion of iodine to an organic compound in the thyroid gland and thus may cause goiter formation.

Substances that enter the thyroid by the same mechanism as iodides can compete with iodine and inhibit its uptake by the thyroid (e.g., perchlorate, which also inhibits iodide recirculation within the thyroid). Iodine uptake can also be reduced by the use of drugs that do not themselves enter the thyroid gland, such as thiocyanate at concentrations greater than 5 mg/dL.

The thyroid gland’s uptake of iodine and its metabolism are stimulated by endogenous and exogenously administered thyrotropic hormone (TSH).

Concomitant treatment with high doses of iodine and lithium salts may contribute to goiter and hypothyroidism. High doses of potassium iodide in combination with potassium-saving diuretics may lead to hyperkalemia.

Special Instructions

It should be taken into account that during therapy with the drug, patients with renal insufficiency may develop hyperkalemia.

Hyperthyroidism or nodular toxic goiter as well as a history of these diseases should be excluded before initiating therapy.

In the presence of predisposition to autoimmune thyroid diseases, antibodies to thyroperoxidase may be formed. The saturation of the thyroid gland with iodine may prevent the accumulation of radioactive iodine used for therapeutic or diagnostic purposes. Because of this, it is not recommended that the drug be taken before an action involving radioactive iodine.

Influence on the ability to drive vehicles and other mechanisms

The drug Iodomarin ^® 200 does not affect the ability to drive vehicles and mechanisms.

Synopsis

Round flat cylindrical white or almost white tablets with a bevel and a groove on one side.

Contraindications

• hypersensitivity to the active ingredient or excipients of the drug;
• manifest hyperthyroidism;
• subclinical hyperthyroidism – in doses exceeding 150 mcg iodine daily;
• During dermatitis herpetiformis (senile);
• lactose intolerance, lactase deficiency or glucose-galactose malabsorption.

The drug should not be used in cases of hypothyroidism, unless the development of the latter is caused by severe iodine deficiency.

The use of the drug should be avoided if radioactive iodine therapy is present or suspected of thyroid cancer.

Side effects

Allergic reactions may occur rarely: skin rash, Quincke’s edema.

Overdose

Symptoms: brown staining of mucous membranes, reflexive vomiting (if starch-containing components are present in food, vomit turns blue), abdominal pain and diarrhea (possible presence of blood in stools). In severe cases, dehydration and shock may develop. Esophageal stenosis has occurred in rare cases. Cases of fatal outcome have been observed only after ingestion of large amounts of iodine (30 – 250 ml of iodine tincture).

In rare cases, prolonged overdose of potassium iodide may lead to the development of so-called “iodism”, i.e. iodine intoxication: metallic taste in the mouth, swelling and irritation of mucous membranes (runny nose, conjunctivitis, gastroenteritis, bronchitis). Potassium iodide can activate latent inflammatory processes such as tuberculosis. Edema, erythema, acne-like and bullous rashes, hemorrhages, fever, and irritability may develop.

Treatment in acute intoxication:Gastric lavage with a solution of starch, protein or 5% sodium thiosulfate solution until all traces of iodine are removed. Symptomatic therapy for disorders of water balance, electrolyte balance, antishock therapy. Treatment in chronic intoxication:discontinuation of the drug.

Treatment of iodine-induced hypothyroidism: cancellation of the drug, normalization of metabolism with thyroid hormones.

Treatment of iodine-induced thyrotoxicosis:in mild forms no treatment is required; in severe forms thyreostatic therapy is required (whose effect is always delayed). In severe cases (thyrotoxic crisis) intensive therapy, plasmapheresis or thyroidectomy are required.

In the case of hyperthyroidism, we cannot talk about overdose per se, because hyperthyroidism can also be caused by the amount of iodine, which in other countries is normal.

Pregnancy use

In pregnancy and breastfeeding the need for iodine increases, so it is especially important to use in sufficient doses to ensure adequate intake of iodine in the mother’s body.

Potassium iodide passes through the placenta and into the breast milk, so the drug can only be used in pregnancy and breast-feeding in the recommended doses.

If a breastfeeding woman is taking potassium iodide, additional potassium iodide is not required for breastfed infants.

In potassium iodide therapy, the amount of iodine in food must be considered.

Similarities

Iodobalance, Iodomarin 100, Potassium iodide